Zhejiang Starry Pharmaceutical Co., Ltd

Short Term Long Term Short Term Comparison Long Term Comparison
  • 603520
  • 1d-3.70%
  • 1w-6.09%
  • 1m-9.15%
  • 1y-34.77%
ATH
  • ATH Price$651.92
  • ATH Date2019-04-30
  • % since ATH-98.20%
  • % to ATH5,462.43%
ATL
  • ATL Price$5.81
  • ATL Date2016-03-09
  • % from ATL101.86%
  • Last Low Price$8.4
  • Last Low Date2024-02-07
  • % From Last Low39.52%
IPO
  • IPO Price$17.50
  • % Current ROI USD-33.03%
  • ATH Price$651.92
  • % ROI ATH 1,122,833.28%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="603520"]

Key Data [addtoany]

Current price $11.72
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Today's High/Low $12.27/$11.64
Volume 1,993,760.00
Previous Close $12.17
52 Week High/Low $18.2631/$7.86
Market Cap 4,168,395,264.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $0.5
Annualized Dividend $0.0164
$11.72
[addtoany]

Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of active ingredient and intermediate X-CT non-ionic contrast agents, and fluoroquinolones in China and internationally.
Its contrast medium products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, gadobenate dimeglumine, iodixanol, gadopentetate dimeglumine, and gadoterate meglumine; and fluoroquinolones products comprise levofloxacin hemihydrate, levofloxacin HCL, levofloxacin acid ester, levofloxacin acid, pazufloxacin, and pazufloxacin mesylate.
The company was founded in 1997 and is based in Xianju, China.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity